SITC x KACTUS

By Hannah Flaherty

October 13, 2025

Menu

What is SITC?

The Society for Immunotherapy of Cancer (SITC) is a professional organization dedicated to advancing the science and application of cancer immunotherapy. It provides a platform for researchers, clinicians, and industry professionals to share knowledge, collaborate, and promote innovative treatments to improve cancer patient outcomes. SITC's annual meeting is one of the largest gatherings in the field, showcasing the latest research and developments in cancer immunotherapy.

Event Overview

Venue: Gaylord National Resort & Convention Center, 201 Waterfront St, Oxon Hill, MD 20745

Dates: November 5th to 9th, 2025

Conference Day 1: Friday, November 7, 2025 – 7:45 AM to 7:00 PM ET

Exhibit hall open from 10:00 AM to 7:00 PM

Conference Day 2: Saturday, November 8, 2025 – 7:15 AM to 8:30 PM ET

Exhibit hall open from 10:00 AM to 6:35 PM

Conference Day 3: Sunday, November 9, 2025 – 8:00 AM to 12:00 PM ET

KACTUS Booth #820

Event Schedule

The SITC 2025 Annual Meeting will feature a dynamic lineup of scientific sessions, workshops, and keynote presentations highlighting the latest breakthroughs in cancer immunotherapy. This year’s program will celebrate 40 years of advancing the field, with topics spanning tumor microenvironment biology, next-generation cellular therapies, bispecifics, biomarkers, and the integration of artificial intelligence in immuno-oncology. The meeting kicks off with pre-conference programs on November 5–6, offering in-depth education and career development opportunities for both established experts and early-career investigators. For the full agenda and program details, visit the SITC 2025 Annual Meeting Schedule.

Day 1 – November 7, 2025

Presidential Welcome 7:45 to 7:50 AM
Awards Ceremony 7:50 to 8:20 AM (Chair: James Gulley, MD, PhD, FACP)
Keynote Address 8:20 to 9:10 AM (Jennifer A. Wargo, MD, MMSc – Targeting the Microbiome to Promote Health and End Cancer)
Break 9:10 to 9:40 AM
Exhibit hall open from 10:00 AM to 7:00 PM
Session 103: Thomas Waldmann Memorial Plenary – Neuro-immunology as an Untapped Opportunity in Cancer Immunotherapy 9:40 to 11:30 AM
Session 104: Clinical Oral Abstract Session 11:30 AM to 12:15 PM
Exhibits & Poster Viewing 12:15 to 1:45 PM
Session 105a: Rapid Oral Abstracts – Basic 12:30 to 1:30 PM
Session 105b: Rapid Oral Abstracts – Clinical 12:30 to 1:30 PM
Concurrent Sessions 106a–106e (Peri-/Neoadjuvant Biomarkers, Microbiota & IO, Immunoprevention, Regulatory Issues in Pediatric Cancers, Oral Abstract Session) 1:45 to 3:25 PM
Break 3:25 to 3:55 PM
Concurrent Sessions 107a–107e (Age-Related Changes in TME, Neuro-Immune Modulation, Immune Regulatory Subsets, Next-Gen IO Viruses/Cells/PD-1 Bispecifics, Oral Abstract Session 2) 3:55 to 5:35 PM
Poster Reception 5:35 to 7:00 PM

Day 2 – November 8, 2025

Organizer Welcome 7:35 to 7:40 AM
Awards Ceremony 7:40 to 8:05 AM
Richard V. Smalley Memorial Award & Lectureship 8:05 to 8:55 AM
Break 8:55 to 9:25 AM
Exhibit hall open from 10:00 AM to 6:35 PM
Session 203: Imaging, Radiomics & Integrated Biomarkers in IO 9:25 to 11:15 AM
Session 204: Hot Topic – Rheumatology for the Oncologist (B Cell-Targeted Therapies) 11:15 AM to 12:15 PM
Exhibits & Poster Viewing 12:15 to 1:45 PM
Session 205a: Rapid Oral Abstracts – Basic 12:15 to 1:15 PM
Concurrent Sessions 206a–206e (Antigen Presentation, TIL Therapies, Innate Immunity, Oral Abstracts, Clinical Trials Updates) 1:45 to 3:25 PM
Break 3:25 to 3:55 PM
Concurrent Sessions 207a–207f (Next-Gen Cell Therapy, Tumor Microenvironment, Computational Immunology, Novel Checkpoints, Systems Biology, Clinical Orals) 3:55 to 5:35 PM
Exhibits & Poster Reception 5:10 to 6:35 PM
40th Anniversary Party featuring The CheckPoints 8:30 PM to 12:00 AM

Day 3 – November 9, 2025

Organizer Welcome 8:00 to 8:05 AM
Session 301: Presidential Session 8:05 to 9:30 AM
Break 9:30 to 9:45 AM
Session 302: Beyond Cytotoxic Chemotherapy – The Next Generation of ADCs for Immune Modulation 9:45 to 11:25 AM
Session 303: Awards Ceremony 11:30 AM to 12:00 PM

About KACTUS

KACTUS specializes in the development and production of high-quality, bioactive recombinant proteins and enzymes that support innovation across antibody drug discovery, immunotherapy, gene therapy, and mRNA therapeutics. With a catalog of over 2,500 recombinant proteins spanning diverse targets, species, tags, and formats, we are committed to meeting the evolving needs of scientists in translational research. Our focus on rigorous quality control and reliable supply ensures the consistency and performance that today’s therapeutic development demands.